Two clinicians appointed to leadership roles with Atlantic Hematology Oncology
Two hematologists-oncologists have assumed key leadership roles at Atlantic Hematology Oncology, part of Atlantic Health System Cancer Care.
Charles M. Farber, MD, PhD, and Michael Anthony Scola, MD, have longtime affiliations with Morristown Medical Center, one of six hospitals in Atlantic Health System.
“Our hematology/oncology patients, physicians and staff are very familiar with the skill, dedication and compassion of Drs. Farber and Scola,” Missak Haigentz Jr., MD, medical director of Atlantic Hematology Oncology, said in the release. “They have been highly regarded members of the Morristown Medical Center community for many years, and we look forward to their new leadership in Atlantic Medical Group and Atlantic Health System.”
Farber will serve as medical director of oncology research development for Atlantic Health System. He will continue to serve as general oncologist with a concentration in malignant hematology.
Farber previously served as division of hematology/oncology at Morristown Medical Center, one of six hospitals within Atlantic Health System. He also has held appointments at Memorial Sloan Kettering Cancer Center, The New York Hospital, Rutgers University, Cancer Institute of New Jersey, Cornell University Medical College and University of Rochester.
“I look forward to continuing to serve my patients at Morristown Medical Center, while helping to build and extend our cancer research network, transforming the way cancer care is delivered in the region,” Farber said in a press release. “It is an exciting time to develop new models of cancer care.”
Scola will serve as director of Atlantic Thrombosis Center, a multidisciplinary program intended to optimize clinical care of blood clotting risk, events and disorders.
Scola has maintained a broad clinical practice for the past 20 years, focusing on malignant and benign hematology. He previously served as course director of pathophysiology at Northeastern University.
“The opportunity to start the Atlantic Thrombosis Center is the culmination of my longstanding interests in blood clotting and its complications,” Scola said in the release. “There is a great need to provide leading-edge care for patients with clotting disorders, and this new center will enable us to dedicate time and resources to providing optimal treatment.”